

# INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011



Atty. Docket No.	03495.0188-01	Appln. No.	10/608,538
Applicant	Yves JACOB et al.		
Filing Date	June 30, 2003	Group:	1645

## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
BLi	6,673,601	January 6, 2004	Jacob et al.	—	—	
BLi	Appl. No. 09/958,672		Jacob et al.	—	—	International Filing Date: April 17, 2000

## FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
BLi	WO 90 11092	10/1990	PCT	—	—	
↓	WO 93 06223	04/1993	PCT	—	—	Abstract
	WO 95/09249	04/1995	PCT	—	—	
↓	EPO 696 191 B1	10/1994	EPO	—	—	Abstract

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BLi	Amengual, B. et al., "Evolution of European Bat Lyssaviruses", <i>J. Gen. Virol.</i> , 78:2319-2328 (1997).
↓	Bahloul, C. et al., "DNA-based Immunization for Exploring the Enlargement of Immunological Cross-reactivity Against the Lyssaviruses", <i>Vaccine</i> , 16:417-425 (1998).
	Benmansour et al., "Antigenicity of Rabies Virus Glycoprotein", <i>J. Virol.</i> , 65(8):4198-4203 (1991).
	Buffett et al., " <i>P. Falciparum</i> Domain Mediating Adhesion to Chondroitin Sulfate A: A Receptor for Human Placental Infection", <i>PNAS</i> , 96(22):12743-48 (1999).
	Coulon et al., "An Avirulent Mutant of Rabies Virus is Unable to Infect Motoneurons <i>In Vivo</i> and <i>In Vitro</i> ", <i>J. Virol.</i> , 72(1):273-278 (1998).
	Desmézières et al.; Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines; <i>J. Gen. Virol.</i> (1999), 80:2343-2351
↓	Dietzschold et al., "Structural and Immunological Characterization of a Linear Virus-Neutralizing Epitope of the Rabies Virus Glycoprotein and its Possible Use in a Synthetic Vaccine", <i>Vaccine</i> , 64(8):3804-3809 (1990).
↓	Donnelly, J. et al., "DNA Vaccines", <i>Annu. Rev. Immunol.</i> , 15:617-648 (1997).

BLi

03/17/2006  
Page 1 of 3

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03495.0188-01	Appln. No.	10/608,538
Applicant	Yves JACOB et al.		
Filing Date	June 30, 2003	Group:	1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
BLI	Editorial, <i>Vaccine</i> , Vol. 14, pp. 579-732 (1996).
BL	Ertl, et al., "Novel Vaccine Approaches", <i>Journal of Immunology</i> , 156:3579-3582 (1996).
BL:	European Commission COST/STD-3, "Advantages of Combined Vaccines", <i>Vaccine</i> , 14(7):693-700 (1996).
	Gaudin, Y., et al., "Reversible Conformational Changes and Fusion Activity of Rabies Virus Glycoprotein", <i>J. Virol.</i> , 65(9):4853-4859 (1991).
	Gaudin, Y. et al., "Biological Function of the Low-pH, Fusion-inactive Conformation of Rabies Virus Glycoprotein (G): G is Transported in a Fusion-inactive State-like Conformation", <i>J. Virol.</i> , 69(9):5528-5533 (1995).
	Gaudin, Y., "Folding of Rabies Virus Glycoprotein: Epitope Acquisition and Interaction with Endoplasmic reticulum Chaperones", <i>J. Virol.</i> , 71(15):3742-3750 (1997).
	Jallet et al., "Chimeric Lyssavirus Glycoproteins with Increased Immunological Potential", <i>Journal of Virology</i> , 73(1):225-233 (1999).
	Lafay et al., "Immunodominant Epitopes Defined by a Yeast-expressed Library of Random Fragments of the Rabies Virus Glycoprotein Map Outside Major Antigenic Sites", <i>J. Gen. Virol.</i> , B77:339-346 (1996).
	Lafon et al., "Antigenic Sites on the CVS Rabies Virus Glycoprotein: Analysis with Monoclonal Antibodies", <i>J. Gen. Virol.</i> , 64:843-845 (1983).
	Lafon, M. et al., "Use of a monoclonal Antibody for Quantitation of Rabies Vaccine Glycoprotein by Enzyme Immunoassay", <i>J. Biol. Standard</i> , 13:295-301 (1985).
	Lang, J. et al., "Randomised Feasibility Trial of Pre-Exposure Rabies Vaccination with DTP-IPV in Infants", <i>The Lancet</i> , 349:1663-1665 (1997).
	Liu et al., "Polynucleotide Vaccines: A Potential New Generation of Vaccines," <i>Proc. Eur. Assoc. Vet. Pharmacol. Toxicol. 6 Meet.</i> , 301, Abstract Only (1994).
	Lodmell, D. et al., "DNA Immunization Protects Nonhuman Primates Against Rabies Virus", <i>Nature Med.</i> , 4(8):949-952 (1998a).
	Lodmell, D. et al., "Gene Gun Particle-Mediated Vaccination with Plasmid DNA Confers Protective Immunity Against Rabies Virus Infection", <i>Vaccine</i> , 16(2/3):115-118 (1998b).
	MacFarlan, R. et al., "T Cell Responses to Cleaved Rabies Glycoprotein and to Synthetic Peptides", <i>J. Immunol.</i> , 133(5):2748-2752 (1984).
	Macy et al., <i>Vet. Clin. North Am small Anim. Pract.</i> , Abstract Only, 26(1):103-109 (1996).
	Mebatsion et al., "Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles", <i>Journal of Virology</i> , 69(3):1444-1451 (1995).
✓	Paoletti et al., <i>PNAS</i> , 93(21):11349-53 (1996).

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03495.0188-01	Appln. No.	10/608,538
Applicant	Yves JACOB et al.		
Filing Date	June 30, 2003	Group:	1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
BL	Pastoret, P-P. et al., "Vaccination Against Rabies", <i>In Veterinary Vaccinology</i> , Pastoret, Eds. (Elsevier):616-628 (1997). s
	Perrin, P. et al., "Rabies Immunosome (Subunit Vaccine) Structure and Immunogenicity", <i>Vaccine</i> , 3:325-332 (1985).
	Perrin, P. et al., "The Influence of the Type of Immunosorbent on Rabies Antibody EIA: Advantages of Purified Glycoprotein over Whole Virus", <i>J. Biol. Standard</i> , 14:95-102 (1986).
	Perrin, P. et al. Interleukin 2 increases protection against experimental rabies, <i>Immunobiology</i> , vol. 177, pp. 199-209 (1988).
	Perrin, P., "Techniques for the Preparation of Rabies Conjugates", <i>In Laboratory Techniques in Rabies</i> , 4 <sup>th</sup> Ed. (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:433-445 (1996a).
	Perrin, P. et al., "The Antigen-Specific Cell-Mediated Immune Response in Mice is Suppressed by Infection with Pathogenic Lyssaviruses", <i>Res. Virol.</i> , 147:289-299 (1996b).
	Rogers, S., et al., Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis, <i>Science</i> , vol. 234, pp. 364-369 (1986).
	Smith, J. et al., "A Rapid Fluorescent Focus Inhibition Test (RFFIT) for Determining Virus-Neutralizing Antibody", <i>In Laboratory Techniques in Rabies</i> , 4 <sup>th</sup> Ed. (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:181-189 (1996).
✓	Thomson, S. et al., "Delivery of Multiple CD8 Cytotoxic Cell Epitopes by DNA Vaccination", <i>J. Immunol.</i> , 160(4):1717-1723 (1998).
BL:	Tine et al., "NYVAC-PF7:A Poxvirus-vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium Falciparum Malaria," <i>Infection and Immunity.</i> , 64(9):3833-3844 (1996).
BL:	Tuffereau et al., "Neuronal Cell Surface Molecules Mediate Specific Binding to Rabies Virus Glycoprotein Expressed by a Recombinant Baculovirus on the Surfaces of Lepidopteran Cells", <i>J. Virol.</i> , 72(2):1085-1091 (1998).
BL:	Wunner, W. et al., "Localization of Immunogenic Domains on the Rabies Virus Glycoprotein," <i>Ann. Inst. Pasteur</i> , 136E:353-362 (1985).
BL:	Xiang, Z. et al., "Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity Against rabies Virus", <i>Virol.</i> , 199:132-140 (1994).

Examiner	Bagun L	Date Considered	03/17/2006
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	